‹ Back to screener

NEULANDLAB.NS Neuland Laboratories Ltd.

Healthcare

Price history

2021-08-23 ₹1523.20
2026-08-21 ₹23365.00
Change over window +1433.94%

Price is the daily close from stored Kite history. The other metrics pair that daily price with the company's periodic filings — each fundamental (revenue, EPS, equity…) is held flat at its latest filed value between annual filings, so a ratio steps at each filing and moves daily only through its price term. A metric with no input on file for this company (e.g. EV/EBITDA for a bank, which has no EBIT) is shown as unavailable, never guessed. Share-count-based metrics use the latest diluted share count against split/bonus-adjusted prices.

Technical indicators

ℹ These reflect only the stock's recent price and volume behavior — not the company's fundamentals — and are not a recommendation to buy or sell. Standard published parameters are used throughout (see each chart's own label); a company with too little stored price history for a given indicator's lookback window shows that plainly below rather than a garbage or misleading value.

MACD (12,26,9), Stochastic Oscillator (14,3) and Money Flow Index (14-day) each carry their own published reference lines/bands (20/80 for the oscillator readings) where one is standard. ADX includes +DI/-DI for direction alongside trend strength; a dashed line marks the commonly published 25 "trending market" reading. ATR is shown in raw rupees here; the price/volume preset screen (below, and on the Screener page) reports it as a % of price so it's comparable across stocks at different price levels. Computed from the same stored daily OHLCV history as the price chart above — no new data source.

Delivery volume

Latest (2026-08-28) 42.6%
Trailing 20-day average 42.3%
Date Traded Qty Delivery Qty Delivery %
2026-08-28 38996 16597 42.56%
2026-08-27 37696 18149 48.15%
2026-08-26 46754 23436 50.13%
2026-08-25 37631 17656 46.92%
2026-08-24 31931 14248 44.62%
2026-08-21 29207 14080 48.21%
2026-08-20 50063 23269 46.48%
2026-08-19 33339 14425 43.27%
2026-08-18 55362 23827 43.04%
2026-08-17 93991 43492 46.27%
2026-08-14 83744 34969 41.76%
2026-08-13 96590 46084 47.71%
2026-08-12 53189 26546 49.91%
2026-08-11 105018 39478 37.59%
2026-08-10 88424 33052 37.38%
2026-08-07 313887 69350 22.09%
2026-08-06 929534 179949 19.36%
2026-08-05 60067 26775 44.58%
2026-08-04 35321 16667 47.19%
2026-08-03 46146 17968 38.94%

Delivery quantity/percentage from the NSE bhavcopy (DELIV_QTY/DELIV_PER) — the share of that day's traded volume that actually settled into a demat account, rather than being squared off intraday. A higher delivery percentage is commonly read as genuine accumulation/distribution rather than speculative same-day trading; this describes recent trading PATTERN, not the company itself, and is not a recommendation to buy or sell. A blank cell is a day NSE itself published no figure for, never a zero. Run python manage.py refresh_delivery_volumes --tickers NEULANDLAB.NS to fetch more history.

Insider trading activity

Disclosed Person Category Type Mode Quantity Value (₹) Resulting stake
26 Mar 2026 Davuluri Saharsh Rao Promoters Pledge Pledge Creation 96000 1161216000 1.52% XBRL
05 Mar 2026 Deepthi Davuluri Promoter Group Buy Gift 12500 0 0.01% XBRL
05 Mar 2026 Davuluri Saharsh Rao Promoters Sell Gift 12500 0 1.52% XBRL
17 Dec 2025 Mr. Gannabathula Venkata Krishna Rama Rao Promoters Sell Gift 6000 0 0.01% XBRL
17 Dec 2025 Ms. Kamala Tayaramma Kommula Promoter Group Buy - 6000 0 0.01% XBRL
24 Sep 2025 Ms. Gannabathula Venkata Vani Sriranganayakamma Promoter Group Buy Gift 9000 0 0.01% XBRL
24 Sep 2025 Mr.Gannabathula Veeravenkata Satyanarayanamurty Promoter Group Buy Gift 10000 0 0.24% XBRL
24 Sep 2025 Mr. Gannabathula Venkata Krishna Rama Rao Promoters Sell Gift 19000 0 0.01% XBRL
01 Mar 2025 Saharsh Rao Davuluri Promoters Sell Gift 79462 0 1.62% XBRL
01 Mar 2025 Davuluri Ownership Trust Promoters Buy Gift 79462 0 25.98% XBRL
25 Feb 2025 Davuluri Ramamohan Rao Promoters Sell Gift 2565979 0 1.63% XBRL
25 Feb 2025 Davuluri Vijaya Rao Promoter Group Sell Gift 608338 0 0.04% XBRL
25 Feb 2025 Davuluri Ownership Trust Promoters Buy Gift 3253890 0 25.36% XBRL
25 Feb 2025 Sucheth Rao Davuluri Promoters Sell Gift 79573 0 2.01% XBRL
05 Dec 2023 Nirupama Sundar Immediate relative Sell Market Sale 500 2687656 0.00% XBRL
24 Aug 2023 Davuluri Saharsh Rao Promoters Buy Gift 33500 0 2.24% XBRL
24 Aug 2023 Davuluri Ramamohan Rao Promoters Sell Gift 33500 0 24.71% XBRL
30 Sep 2022 Payal Gupta Immediate relative Buy Market Purchase 1267 1619375 0.00% XBRL
01 Sep 2022 Nirupama Sundar Immediate relative Buy Market Purchase 900 1039089 0.00% XBRL
22 Mar 2022 Davuluri Rohini Niveditha Rao Promoter Group Sell Gift 77634 0 0.66% XBRL

SEBI PIT (Prohibition of Insider Trading) Regulation 7 disclosures — designated persons (promoters, directors, KMPs, and their immediate relatives) reporting their own dealing in the company's securities, as NSE publishes them. Distinct from the SAST (Regulation 29 substantial-acquisition) filings on the market-wide SAST activity page. Public record only — this is descriptive disclosure data, not a signal, and is not a recommendation to buy or sell. Run python manage.py refresh_insider_trades --tickers NEULANDLAB.NS to fetch more.

Ratios as of FY2025-26 (Annual) · Price ₹23301.00 INR (live) · fetched 2026-08-23 23:40 price stale

Extract this company (financials + ratios + citations): CSV · XLSX

Ratios

P/E
82.58
P/E = Price / EPS
Source trace
P/E = Price / (ProfitOrLossAttributableToOwnersOfParent / PaidUpValueOfEquityShareCapital ÷ FaceValueOfEquityShareCapital) → ₹23,301.00 / (₹3,639,984,000 / 12,900,500 shares) = ₹23,301.00 / ₹282.16 EPS
FY2025-26 · Annual filing
ROE
19.42%
ROE = Net Income / Shareholder Equity
Source trace
ROE = ProfitOrLossAttributableToOwnersOfParent / EquityAttributableToOwnersOfParent → ₹3,639,984,000 / ₹18,744,729,000 = 19.42%
FY2025-26 · Annual filing
Debt/Equity
0.10
Debt/Equity = Total Debt / Shareholder Equity
Source trace
Debt/Equity = BorrowingsCurrent + BorrowingsNoncurrent / EquityAttributableToOwnersOfParent → ₹1,966,131,000 / ₹18,744,729,000 = 0.10
FY2025-26 · Annual filing
Current Ratio
2.09
Current Ratio = Current Assets / Current Liabilities
Source trace
Current Ratio = CurrentAssets / CurrentLiabilities → ₹14,831,288,000 / ₹7,101,980,000 = 2.09
FY2025-26 · Annual filing
ROCE
24.77%
ROCE = EBIT / (Shareholder Equity + Total Debt)
Source trace
ROCE = ProfitBeforeExceptionalItemsAndTax + FinanceCosts / (EquityAttributableToOwnersOfParent + BorrowingsCurrent + BorrowingsNoncurrent) → ₹5,129,245,000 / (₹18,744,729,000 + ₹1,966,131,000) = 24.77%
FY2025-26 · Annual filing
Dividend Yield
0.05%
Dividend Yield = (Dividends Paid / Diluted Shares Outstanding) / Price

This is cash paid during the fiscal year, not a per-share rate declared for it (no such element exists in the filing data) — timing can straddle interim/final dividends across years, and pre-FY2020-21 figures may include the since-abolished Dividend Distribution Tax, reading higher than later years for that reason alone.

Source trace
Dividend Yield = (|DividendsPaidClassifiedAsFinancingActivities| / PaidUpValueOfEquityShareCapital ÷ FaceValueOfEquityShareCapital) / Price → (₹153,959,000 / 12,900,500 shares) / ₹23,301.00 = ₹11.93 / ₹23,301.00
FY2025-26 · Annual filing

Growth & earnings trend

Revenue & Profit CAGR

Revenue (3y, 3.0y actual) 19.3%
Net Profit (3y) N/A
Revenue (5y, 3.0y actual) 19.3%
Net Profit (5y) N/A
Revenue (10y, 3.0y actual) 19.3%
Net Profit (10y) N/A

Operating Margin Trend

Expanding

FY2022-23 19.2%
FY2023-24 26.7%
FY2024-25 18.8%
FY2025-26 25.4%

ROCE Trajectory

FY2022-23 20.5%
FY2023-24 30.4%
FY2024-25 16.8%
FY2025-26 24.8%

Earnings Quality

Net profit or operating cash flow was zero or negative in the base or latest year — a growth-rate comparison isn't defined across a sign change.

Sector-Relative Percentile (Healthcare)

ROE 83th
ROCE 78th
Debt/Equity 52th
P/E 24th

Quarterly trend

Revenue Net Profit Net Profit (loss quarter)
Metric (to shareholders basis) Q4 FY2023-24 Q1 FY2024-25 Q2 FY2024-25 Q3 FY2024-25 Q4 FY2024-25 Q1 FY2025-26 Q2 FY2025-26 Q3 FY2025-26 Q4 FY2025-26 Q1 FY2026-27 Source
Revenue ₹385.01 Cr. ₹439.60 Cr. ₹310.84 Cr. ₹398.03 Cr. ₹328.36 Cr. ₹292.75 Cr. ₹514.27 Cr. ₹439.71 Cr. ₹776.25 Cr. ₹641.58 Cr. RevenueFromOperations
Net Profit ₹67.56 Cr. ₹97.87 Cr. ₹32.84 Cr. ₹101.59 Cr. ₹27.81 Cr. ₹13.90 Cr. ₹96.85 Cr. ₹40.57 Cr. ₹212.67 Cr. ₹147.67 Cr. ProfitLossForPeriod

Primary figures are Revenue from Operations and Net Profit attributable to shareholders — the basis the ratios use. Where they differ, the companion Gross revenue (incl. inter-segment) and incl. minority net profit (the totals a news headline usually quotes) are shown beneath, each traceable to its own XBRL element. Quarters shown are however many are actually stored (up to 10) — run python manage.py refresh_quarterly_trend --tickers NEULANDLAB.NS to fetch more.

Source document — income statement (FY2025-26, raw filing line items)

View original filing on NSE ↗ NSE's own filing document, opened in a new tab — StockProof links to it, never stores a copy.

ProfitOrLossAttributableToOwnersOfParent3639984000.0
PaidUpValueOfEquityShareCapital ÷ FaceValueOfEquityShareCapital12900500.0
Source document — balance sheet (FY2025-26, raw filing line items)

View original filing on NSE ↗ NSE's own filing document, opened in a new tab — StockProof links to it, never stores a copy.

CurrentAssets14831288000.0
CurrentLiabilities7101980000.0
EquityAttributableToOwnersOfParent18744729000.0
BorrowingsCurrent + BorrowingsNoncurrent1966131000.0

My notes